ATE321783T1 - Zinkfreie insulinkristalle für die verwendung in medikamenten, die über die lunge verabreicht werden. - Google Patents

Zinkfreie insulinkristalle für die verwendung in medikamenten, die über die lunge verabreicht werden.

Info

Publication number
ATE321783T1
ATE321783T1 AT98907916T AT98907916T ATE321783T1 AT E321783 T1 ATE321783 T1 AT E321783T1 AT 98907916 T AT98907916 T AT 98907916T AT 98907916 T AT98907916 T AT 98907916T AT E321783 T1 ATE321783 T1 AT E321783T1
Authority
AT
Austria
Prior art keywords
zinc
lungs
free insulin
insulin crystals
medications administered
Prior art date
Application number
AT98907916T
Other languages
English (en)
Inventor
Svend Havelund
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE321783T1 publication Critical patent/ATE321783T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT98907916T 1997-03-20 1998-03-20 Zinkfreie insulinkristalle für die verwendung in medikamenten, die über die lunge verabreicht werden. ATE321783T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK31797 1997-03-20

Publications (1)

Publication Number Publication Date
ATE321783T1 true ATE321783T1 (de) 2006-04-15

Family

ID=8092195

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98907916T ATE321783T1 (de) 1997-03-20 1998-03-20 Zinkfreie insulinkristalle für die verwendung in medikamenten, die über die lunge verabreicht werden.

Country Status (17)

Country Link
US (2) US20070093411A1 (de)
EP (2) EP1005490B1 (de)
JP (1) JP3764174B2 (de)
KR (1) KR20000076419A (de)
CN (1) CN1259142A (de)
AT (1) ATE321783T1 (de)
AU (1) AU742591B2 (de)
BR (1) BR9808285A (de)
CA (1) CA2283705A1 (de)
DE (1) DE69834028T2 (de)
ES (1) ES2260832T3 (de)
HU (1) HUP0000547A3 (de)
IL (1) IL131796A0 (de)
NO (1) NO994520L (de)
PL (1) PL335777A1 (de)
RU (1) RU2198181C2 (de)
WO (1) WO1998042749A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500933B1 (en) 1997-09-05 2002-12-31 Altus Biologics Inc. Methods of preparing carbohydrate crosslinked glycoprotein crystals
ATE397013T1 (de) 1997-09-05 2008-06-15 Altus Pharmaceuticals Inc Kohlenhydrat-vernetzte glykoproteinkristalle
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
WO1999055310A1 (en) * 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
SG121739A1 (en) * 1998-04-27 2006-05-26 Altus Pharmaceuticals Inc Stabilized protein crystals, formulations containing them and methods of making them
DE19903125B4 (de) * 1999-01-27 2006-01-05 Sanofi-Aventis Deutschland Gmbh Verfahren zur Trocknung von Kristallen von Insulin oder Insulinanaloga
AU4450700A (en) * 1999-04-27 2000-11-10 Eli Lilly And Company Insulin crystals for pulmonary administration
GB0011807D0 (en) * 2000-05-16 2000-07-05 Quadrant Holdings Cambridge Formulation for inhalation
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
DE10250297A1 (de) * 2002-10-29 2004-05-19 Aventis Pharma Deutschland Gmbh Kristalle von Insulinanaloga und Verfahren zu ihrer Herstellung
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
KR101159559B1 (ko) * 2003-08-05 2012-06-26 노보 노르디스크 에이/에스 신규의 인슐린 유도체
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
WO2005072803A1 (en) 2004-01-16 2005-08-11 Biodel, Inc. Sublingual drug delivery device
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
KR100798333B1 (ko) * 2005-08-03 2008-01-28 고려대학교 산학협력단 락토오스 운반체와 혼합건조된 폐 전달용 인슐린미세결정분말
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
EP3202394A1 (de) 2009-07-06 2017-08-09 Sanofi-Aventis Deutschland GmbH Wässrige insulinzubereitungen enthaltend methionin
PL2464655T3 (pl) * 2009-08-11 2017-08-31 Biocon Limited Procesy chromatograficzne
PE20121316A1 (es) 2009-11-13 2012-10-05 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
PT2554183T (pt) 2009-11-13 2018-07-09 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
US20140148384A1 (en) 2010-08-30 2014-05-29 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CN106794156B (zh) * 2014-07-08 2021-03-09 美药星制药股份有限公司 微粒化胰岛素、微粒化胰岛素类似物及其制备方法
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN104761632A (zh) * 2015-04-14 2015-07-08 珠海联邦制药股份有限公司 一种地特胰岛素结晶的制备方法及应用
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
CA2996455A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
WO2017032795A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
EP3341402A1 (de) 2015-08-25 2018-07-04 Novo Nordisk A/S Neuartige insulinderivate und medizinische verwendungen davon
US10322168B2 (en) 2016-01-07 2019-06-18 Amphastar Pharmaceuticals, Inc. High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
CN106749616B (zh) * 2016-12-19 2021-09-03 华润昂德生物药业有限公司 B30位苏氨酸缺失人胰岛素晶体的制备方法
CN109957001B (zh) * 2017-12-26 2022-11-18 甘李药业股份有限公司 甘赖脯胰岛素结晶的制备方法
PL238016B1 (pl) * 2018-07-06 2021-06-28 Bioton Spolka Akcyjna Krystaliczna, bezcynkowa postać insuliny glargine i sposób jej otrzymywania
FI4073097T3 (fi) 2019-12-11 2024-08-13 Novo Nordisk As Uusia insuliinianalogeja ja niiden käyttötapoja

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE3327928A1 (de) * 1983-08-03 1985-02-21 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten
RU2027444C1 (ru) * 1992-05-08 1995-01-27 Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Способ получения инсулина
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
SI0792290T1 (en) * 1993-09-17 2001-12-31 Novo Nordisk As Acylated insulin
EP0748213B1 (de) * 1994-03-07 2004-04-14 Nektar Therapeutics Verfahren und mittel zur verabreichung von insulin über die lunge
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US5700904A (en) * 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität

Also Published As

Publication number Publication date
IL131796A0 (en) 2001-03-19
KR20000076419A (ko) 2000-12-26
CN1259142A (zh) 2000-07-05
RU2198181C2 (ru) 2003-02-10
PL335777A1 (en) 2000-05-22
EP1005490A1 (de) 2000-06-07
BR9808285A (pt) 2000-05-16
JP3764174B2 (ja) 2006-04-05
US20090311326A9 (en) 2009-12-17
NO994520D0 (no) 1999-09-17
DE69834028D1 (de) 2006-05-18
CA2283705A1 (en) 1998-10-01
EP1627642A2 (de) 2006-02-22
JP2001506272A (ja) 2001-05-15
AU742591B2 (en) 2002-01-10
US20070093411A1 (en) 2007-04-26
HUP0000547A3 (en) 2002-11-28
EP1005490B1 (de) 2006-03-29
NO994520L (no) 1999-09-17
HUP0000547A2 (hu) 2000-08-28
US20070292520A1 (en) 2007-12-20
AU6612098A (en) 1998-10-20
ES2260832T3 (es) 2006-11-01
DE69834028T2 (de) 2006-12-07
EP1627642A3 (de) 2006-04-19
WO1998042749A1 (en) 1998-10-01

Similar Documents

Publication Publication Date Title
ATE321783T1 (de) Zinkfreie insulinkristalle für die verwendung in medikamenten, die über die lunge verabreicht werden.
ATE106389T1 (de) Neue benzoesäure- und phenylessigsäurederivate, ihre herstellung und verwendung als heilmittel.
SE9801992D0 (sv) New 3-aryl-2-hydroxypropionic acid derivative I
DE3870717D1 (de) Essigsaeure aus aethan, aethylen und sauerstoff.
DE3580616D1 (de) Mitomycinderivate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
EP0237200A3 (en) Stabilized pharmaceutical composition comprising a benzimidazole compound, its production and its use as an antiulcer agent
DE3860503D1 (de) 10-dihydro-10-deoxo-11-azaerythronolid-a-verbindungen,verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung in arzneimitteln und in deren herstellung.
EP1002796A3 (de) Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
DE3877406D1 (de) Benzothiazolinon-derivate, ihre herstellung und pharmazeutische zusammensetzung.
DE3876400D1 (de) Aminosaeure-imid-derivate, ihre verwendung und diese enthaltende medizinische zusammensetzungen.
ATE68694T1 (de) Ionenaustauscherharze beladen mit chinoloncarbonsaeurederivaten, ihre herstellung und verwendung.
DE68909958D1 (de) Phenoxyessigsäure-Derivate, ihre Herstellung, pharmazeutische Zusammensetzungen, die sie enthalten, und deren Verwendung.
DE3869257D1 (de) N-aminobutyl-n-phenylarylamid-derivate, ihre herstellung und ihre verwendung in der heilkunde.
ATE40826T1 (de) 4'-demethyl-4-epipodophyllotoxinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
DE3778924D1 (de) Pyridazinon-derivate, deren herstellung und insektizide, akarizide, nematizide, fungizide zusammenstellungen.
EP0310918A3 (de) Peptidartige Aminosäurederivate
SE8700137D0 (sv) Diuretisk komposition
DE3863191D1 (de) Substituierte aminderivate, ihre herstellung und verwendung.
DE3686699D1 (de) P-aminophenole, ihre derivate und verwendung zur herstellung eines medikaments.
DE3382247D1 (de) Vinylcarbonsaeure-derivate, ihre herstellung und verwendung.
EP0214823A3 (de) Alkylamidderivate mit H2-rezeptorantagonistischer und zytoprotektiver Aktivität
DE3883297D1 (de) Phenolderivate, ihre herstellung und verwendung.
DE3684334D1 (de) Antibiotika, "chloropolysporine b und c" genannt, ein verfahren zu ihrer herstellung und ihre therapeutische und veterinaere verwendung.
EP0672052A1 (de) Tachyquinin antagonisten, ihre herstellung und ihre verwendung in pharmazeutischen formulierungen.
DE3577986D1 (de) Substituierte azetidinonverbindungen, deren herstellung und ihre enthaltenden arzneimittel.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties